Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

Howard L. Kaufman, Seth Cohen, Ken Cheung, Gail DeRaffele, Josephine Mitcham, Dorota Moroziewicz, Jeffrey Schlom, Charles Hesdorffer

Research output: Contribution to journalArticle

Abstract

Successful immunotherapy of established tumors depends on overcoming the suppressive influence of the local tumor microenvironment. The direct injection of vaccinia virus expressing the B7.1 (CD80) costimulatory molecule into melanoma lesions resulted in local and systemic immunity with associated clinical responses. Therefore, we sought to evaluate the effects of a vaccinia virus expressing three costimulatory molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM), in patients with metastatic melanoma. A standard dose escalation phase I clinical trial was performed. Thirteen patients were enrolled and 12 were available for follow-up. Local vaccination was feasible, with only low-grade injection site reactions associated with mild fatigue and myalgia reported. There was one occurrence of grade 1 vitiligo. Overall there was a 30.7% objective clinical response, with one patient achieving a complete response for more than 22 months. An inverse association was detected between anti-vaccinia antibody and anti-vaccinia T cell responses. Patients who failed to respond to vaccination but received high-dose interleukin-2 had a trend toward improved survival. Collectively, these results confirm the safety profile and feasibility of direct injection of vaccinia virus expressing multiple costimulatory molecules in patients with established tumors. Further clinical investigation is needed to better define the role of antigen, adjuvant cytokines, costimulation, and cross-presentation in the host immune response to local vaccination with vaccinia viruses expressing immunomodulatory molecules.

Original languageEnglish (US)
Pages (from-to)239-244
Number of pages6
JournalHuman Gene Therapy
Volume17
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Vaccinia virus
Vaccinia
Vaccination
Neoplasms
Injections
Melanoma
CD58 Antigens
Cross-Priming
Therapeutics
Vitiligo
Clinical Trials, Phase I
Tumor Microenvironment
Myalgia
Intercellular Adhesion Molecule-1
Immunotherapy
Interleukin-2
Fatigue
Anti-Idiotypic Antibodies
Immunity
Cytokines

ASJC Scopus subject areas

  • Genetics

Cite this

Kaufman, H. L., Cohen, S., Cheung, K., DeRaffele, G., Mitcham, J., Moroziewicz, D., ... Hesdorffer, C. (2006). Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Human Gene Therapy, 17(2), 239-244. https://doi.org/10.1089/hum.2006.17.239

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. / Kaufman, Howard L.; Cohen, Seth; Cheung, Ken; DeRaffele, Gail; Mitcham, Josephine; Moroziewicz, Dorota; Schlom, Jeffrey; Hesdorffer, Charles.

In: Human Gene Therapy, Vol. 17, No. 2, 02.2006, p. 239-244.

Research output: Contribution to journalArticle

Kaufman, HL, Cohen, S, Cheung, K, DeRaffele, G, Mitcham, J, Moroziewicz, D, Schlom, J & Hesdorffer, C 2006, 'Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors', Human Gene Therapy, vol. 17, no. 2, pp. 239-244. https://doi.org/10.1089/hum.2006.17.239
Kaufman, Howard L. ; Cohen, Seth ; Cheung, Ken ; DeRaffele, Gail ; Mitcham, Josephine ; Moroziewicz, Dorota ; Schlom, Jeffrey ; Hesdorffer, Charles. / Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. In: Human Gene Therapy. 2006 ; Vol. 17, No. 2. pp. 239-244.
@article{4fefd38cbf5846328ae4d92f942660cc,
title = "Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors",
abstract = "Successful immunotherapy of established tumors depends on overcoming the suppressive influence of the local tumor microenvironment. The direct injection of vaccinia virus expressing the B7.1 (CD80) costimulatory molecule into melanoma lesions resulted in local and systemic immunity with associated clinical responses. Therefore, we sought to evaluate the effects of a vaccinia virus expressing three costimulatory molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM), in patients with metastatic melanoma. A standard dose escalation phase I clinical trial was performed. Thirteen patients were enrolled and 12 were available for follow-up. Local vaccination was feasible, with only low-grade injection site reactions associated with mild fatigue and myalgia reported. There was one occurrence of grade 1 vitiligo. Overall there was a 30.7{\%} objective clinical response, with one patient achieving a complete response for more than 22 months. An inverse association was detected between anti-vaccinia antibody and anti-vaccinia T cell responses. Patients who failed to respond to vaccination but received high-dose interleukin-2 had a trend toward improved survival. Collectively, these results confirm the safety profile and feasibility of direct injection of vaccinia virus expressing multiple costimulatory molecules in patients with established tumors. Further clinical investigation is needed to better define the role of antigen, adjuvant cytokines, costimulation, and cross-presentation in the host immune response to local vaccination with vaccinia viruses expressing immunomodulatory molecules.",
author = "Kaufman, {Howard L.} and Seth Cohen and Ken Cheung and Gail DeRaffele and Josephine Mitcham and Dorota Moroziewicz and Jeffrey Schlom and Charles Hesdorffer",
year = "2006",
month = "2",
doi = "10.1089/hum.2006.17.239",
language = "English (US)",
volume = "17",
pages = "239--244",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

AU - Kaufman, Howard L.

AU - Cohen, Seth

AU - Cheung, Ken

AU - DeRaffele, Gail

AU - Mitcham, Josephine

AU - Moroziewicz, Dorota

AU - Schlom, Jeffrey

AU - Hesdorffer, Charles

PY - 2006/2

Y1 - 2006/2

N2 - Successful immunotherapy of established tumors depends on overcoming the suppressive influence of the local tumor microenvironment. The direct injection of vaccinia virus expressing the B7.1 (CD80) costimulatory molecule into melanoma lesions resulted in local and systemic immunity with associated clinical responses. Therefore, we sought to evaluate the effects of a vaccinia virus expressing three costimulatory molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM), in patients with metastatic melanoma. A standard dose escalation phase I clinical trial was performed. Thirteen patients were enrolled and 12 were available for follow-up. Local vaccination was feasible, with only low-grade injection site reactions associated with mild fatigue and myalgia reported. There was one occurrence of grade 1 vitiligo. Overall there was a 30.7% objective clinical response, with one patient achieving a complete response for more than 22 months. An inverse association was detected between anti-vaccinia antibody and anti-vaccinia T cell responses. Patients who failed to respond to vaccination but received high-dose interleukin-2 had a trend toward improved survival. Collectively, these results confirm the safety profile and feasibility of direct injection of vaccinia virus expressing multiple costimulatory molecules in patients with established tumors. Further clinical investigation is needed to better define the role of antigen, adjuvant cytokines, costimulation, and cross-presentation in the host immune response to local vaccination with vaccinia viruses expressing immunomodulatory molecules.

AB - Successful immunotherapy of established tumors depends on overcoming the suppressive influence of the local tumor microenvironment. The direct injection of vaccinia virus expressing the B7.1 (CD80) costimulatory molecule into melanoma lesions resulted in local and systemic immunity with associated clinical responses. Therefore, we sought to evaluate the effects of a vaccinia virus expressing three costimulatory molecules, B7.1, ICAM-1, and LFA-3 (rV-TRICOM), in patients with metastatic melanoma. A standard dose escalation phase I clinical trial was performed. Thirteen patients were enrolled and 12 were available for follow-up. Local vaccination was feasible, with only low-grade injection site reactions associated with mild fatigue and myalgia reported. There was one occurrence of grade 1 vitiligo. Overall there was a 30.7% objective clinical response, with one patient achieving a complete response for more than 22 months. An inverse association was detected between anti-vaccinia antibody and anti-vaccinia T cell responses. Patients who failed to respond to vaccination but received high-dose interleukin-2 had a trend toward improved survival. Collectively, these results confirm the safety profile and feasibility of direct injection of vaccinia virus expressing multiple costimulatory molecules in patients with established tumors. Further clinical investigation is needed to better define the role of antigen, adjuvant cytokines, costimulation, and cross-presentation in the host immune response to local vaccination with vaccinia viruses expressing immunomodulatory molecules.

UR - http://www.scopus.com/inward/record.url?scp=33144480152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144480152&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.239

DO - 10.1089/hum.2006.17.239

M3 - Article

C2 - 16454657

AN - SCOPUS:33144480152

VL - 17

SP - 239

EP - 244

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -